Noble Financial Initiates Coverage on Idera Pharmaceuticals (IDRA)
More News related to IDRA
- Idera Pharma (IDRA) Issues Update on Drug Candidate Pipeline Target to Toll-Like Receptors
- Idera Pharmaceuticals Provides Update on Drug Candidate Pipeline Targeted to Toll-like Receptors
- Idera Pharmaceuticals Announces Presentations of Preclinical Data on Modulation of Toll-like Receptors 3, 7, and 9 through Antisense
- Idera Pharmaceuticals to Present at Noble Financial Capital Market's Fifth Annual Equity Conference
- Idera Pharmaceuticals to Present at BIO Business Forum and Participate in Panel at BIO 2009
Noble Financial initiates coverage on Idera Pharmaceuticals (Nasdaq: IDRA) with a Buy.
Idera Pharmaceuticals, Inc. (Idera) is a biotechnology company engaged in the discovery and development of synthetic deoxyribonucleic acid (DNA)-and ribonucleic acid (RNA)-based drug candidates targeted to Toll-Like Receptors (TLRs), to treat infectious diseases, autoimmune diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants.
Related Categories
New CoverageStocks Mentioned
-0.11Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
